What people are reporting about LL-37 for chronic infection contexts

You test positive for Lyme, get treated, and don't get better. Or you don't test positive, but something is clearly wrong, and the standard workup finds nothing, and the fatigue and the joint pain and the cognitive difficulty have been there for two years. You end up in a forum where someone asks about biofilms. You end up reading about cathelicidins. Eventually you end up reading about LL-37.

LL-37 is the only member of the cathelicidin family of antimicrobial peptides expressed in humans. It is produced by epithelial cells, neutrophils, and other immune cells in response to infection, inflammation, and — this matters — vitamin D signaling. Its biological role is broad: direct antimicrobial activity against bacteria, fungi, and some viruses; modulation of the inflammatory response; facilitation of wound healing; and, most relevant to the chronic infection communities where it gets discussed, activity against biofilm-forming organisms. Biofilms are structured communities of bacteria or other microorganisms that encase themselves in a protective matrix and become dramatically more resistant to both immune responses and conventional antibiotics. The hypothesis that chronic, treatment-resistant infections involve biofilm formation is a significant focus in functional and integrative medicine, and it is part of why LL-37 shows up in chronic Lyme, chronic sinusitis, and similar communities.

The laboratory evidence for LL-37's antimicrobial and antibiofilm properties is real and reasonably extensive — this is a well-studied peptide in basic science terms. What is not established is whether exogenous LL-37 administered by injection replicates, supplements, or is even equivalent to the endogenous peptide in its various biological roles. The jump from "LL-37 has these properties in cell culture and animal models" to "injecting synthetic LL-37 will address a chronic biofilm infection in a human" is a large one, and the clinical trial evidence to support that jump does not currently exist. Community members who are sophisticated about the distinction between preclinical evidence and clinical evidence acknowledge this directly. Others do not, and the biofilm framing can make the case for LL-37 sound more settled than it is.

The chronic Lyme community is one of the primary contexts where LL-37 comes up. The functional medicine framework associated with researchers and practitioners in this space — drawing on the work of writers like Stephen Buhner and concepts from researchers like Trevor Marshall around immune dysregulation — emphasizes the role of bacterial persistence, biofilm formation, and immune dysfunction in ongoing post-infection symptomatology. LL-37 fits into this framework as a potentially relevant intervention because of its cathelicidin antimicrobial and biofilm-disrupting properties and because endogenous LL-37 production is known to be impaired in some chronic illness contexts. The Marshall Protocol specifically emphasizes vitamin D receptor dysregulation as central to chronic disease, and LL-37 production is downstream of active vitamin D (1,25-dihydroxyvitamin D) signaling — which means the question of why a given patient might have suboptimal LL-37 activity is not entirely separate from their vitamin D status and metabolism. Community discussions that draw on this framework tend to be detailed and mechanistically engaged, which does not make them clinically validated but does make them worth reading carefully.

Chronic sinusitis with a biofilm component is a second major context. The sinus microbiome research identifying biofilm-forming organisms in refractory chronic rhinosinusitis has a legitimate clinical basis — this is an area of active mainstream investigation. The community use of LL-37 in this context is typically described as intranasal or injectable, and some users describe it alongside saline irrigation and other antimicrobial interventions. The reports in this space tend to be somewhat more measured than the Lyme community reports, perhaps because the outcome (sinus symptom improvement) is more tractable to self-observation than the diffuse symptoms of chronic Lyme.

The intersection with mast cell activation and chronic illness communities is worth noting. This is a population with heightened sensitivity to both pharmacological interventions and to the immune modulation that LL-37 is proposed to induce. Some community members in this space describe significant reactions to initial dosing — which is a relevant signal, given that LL-37 at higher levels is pro-inflammatory as well as antimicrobial, and that immune modulation in a dysregulated immune system is not straightforwardly beneficial.

The side effect reports from community users who have tried LL-37 by injection are consistent enough to warrant careful attention. Flu-like symptoms — fatigue, mild fever, muscle aches, a general sense of feeling unwell — appear commonly in initial dosing descriptions, particularly at higher doses or in the first days of a protocol. Community members typically frame this as a "detox" or "die-off" response, interpreting the symptoms as evidence that the compound is working. This interpretation may be accurate; it may also reflect the pro-inflammatory properties of LL-37 at doses that exceed its normal physiological range. The distinction is clinically meaningful and essentially impossible to make without medical evaluation of what is actually happening during those initial reactions. The mast cell community, in particular, should note that the flu-like reaction profile overlaps significantly with mast cell activation reactions, and that the assumption that it is a positive sign rather than an adverse one requires more than community consensus to evaluate.

The cost of LL-37 is a recurring theme. It is among the more expensive research peptides — compounding costs for injectable LL-37 are substantially higher than for more common peptides, which already carry meaningful cost. Legitimate compounding pharmacy availability in the US is limited; some specialized pharmacies working in functional medicine spaces have offered it, but it is not widely available through standard compounding channels. As with other compounds in this space, the practical reality for most community users is gray-market research peptide sourcing, with all the identity and purity uncertainty that involves. In a population that is often already dealing with a difficult illness and limited resources, the cost and sourcing complexity are not minor considerations.

Community-positivity bias deserves special emphasis in this context. The chronic Lyme and post-infection communities are among the most challenging populations to evaluate for self-reported treatment outcomes, for reasons that have nothing to do with dishonesty. These are people who are often very ill, often dismissed by conventional medicine, and who have strong motivation to find and report something that helps. Placebo and expectation effects are real and meaningful in chronic illness contexts. Spontaneous fluctuation in chronic illness symptoms is also real — people often try a new intervention during a symptomatic period and feel better as the natural course of that fluctuation resolves. None of this means the reports are worthless. It means they require an extra degree of interpretive humility that is sometimes absent from the most enthusiastic corners of these communities.

LL-37 has no FDA approval for any of the uses described here. The clinical trial evidence for injectable use in chronic infection contexts is essentially nonexistent. The preclinical evidence for its antimicrobial and antibiofilm properties is real but does not constitute evidence of clinical efficacy in the human conditions these communities are discussing. For anyone navigating chronic infection, post-acute infection syndrome, or related complex illness, the LL-37 conversation is one data point in a much larger conversation that needs to happen with a qualified prescribing provider — ideally one who is familiar with both the legitimate scientific literature and the practical realities of functional medicine peptide use.

This is a community conversation. Reading it as anything more is where the risk enters.